Biotech

All Articles

YolTech offers China liberties to gene modifying therapy for $29M

.4 months after Chinese genetics modifying provider YolTech Therapeutics took its own cholesterol le...

Addex inventory increases after Indivior offers up to $300M for substance

.Indivior is picking up a small particle allosteric modulator created to manage element usage condit...

Molecular Partners adjusts AML trial over 'suboptimal exposure'

.Molecular Companions has recognized "suboptimal direct exposure" to its own tetra-specific T-cell e...

Despite blended market, a financial backing resurgence could be can be found in Europe: PitchBook

.While the biotech financial investment scene in Europe has decreased relatively complying with a CO...

8 months after a $213M fundraise, gene editor Volume produces decreases

.After rearing $213 thousand in 2023-- among the year's biggest private biotech rounds-- Volume Bios...

BioMarin develops exec team with biotech vets-- Chutes &amp Ladders

.Invite to today's Chutes &amp Ladders, our roundup of substantial management hirings, firings and a...

Biopharma Q2 VC attacked highest level since '22, while M&ampA slowed

.Equity capital backing in to biopharma rose to $9.2 billion all over 215 deals in the second quarte...

Bicara, Zenas look for IPOs to press late-phase assets toward market

.Bicara Therapeutics and Zenas Biopharma have provided clean motivation to the IPO market along with...

Genentech to close cancer cells immunology investigation team

.Genentech will certainly shut its own cancer cells immunology research division, and system head as...

Kezar drops strong lump but to verify its worth in phase 1 trial

.Kezar Life Sciences is dropping its own dim period 1 solid tumor drug as the biotech goes all-in on...